Roth Capital Issues Optimistic Outlook for BRTX Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Equities researchers at Roth Capital raised their Q3 2024 earnings per share estimates for shares of BioRestorative Therapies in a research report issued on Tuesday, November 5th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.35) per share for the quarter, up from their prior estimate of ($0.36). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.83) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.37) EPS, FY2024 earnings at ($1.76) EPS, FY2025 earnings at ($1.12) EPS and FY2026 earnings at ($1.18) EPS.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.06. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative return on equity of 107.65% and a negative net margin of 6,898.28%. During the same period in the previous year, the company posted ($0.77) EPS.

Separately, Roth Mkm boosted their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th.

BioRestorative Therapies Trading Down 3.0 %

Shares of NASDAQ:BRTX opened at $1.60 on Thursday. The stock has a 50 day moving average of $1.63 and a 200 day moving average of $1.58. The company has a market cap of $11.07 million, a PE ratio of -0.78 and a beta of 63.40. BioRestorative Therapies has a 12-month low of $1.03 and a 12-month high of $3.67.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.